Miles Nunn
Chief Tech/Sci/R&D Officer chez AKARI THERAPEUTICS, PLC
Fortune : - $ au 31/07/2023
Profil
Miles Nunn is currently the Chief Scientific Officer at Akari Therapeutics Plc since 2015.
Prior to this, he worked as a Director at Amplion Ltd., a Scientific Research Manager at Evolutec Group Plc, and as the Chief Scientific Officer at Volution Immuno Pharmaceuticals SA. Dr. Nunn holds a doctorate degree from the University of Oxford and an undergraduate degree from University College London.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AKARI THERAPEUTICS PLC
-.--% | 31/03/2023 | 0 ( -.--% ) | - $ | 31/07/2023 |
Postes actifs de Miles Nunn
| Sociétés | Poste | Début |
|---|---|---|
| AKARI THERAPEUTICS, PLC | Chief Tech/Sci/R&D Officer | 01/09/2015 |
Anciens postes connus de Miles Nunn
| Sociétés | Poste | Fin |
|---|---|---|
Evolutec Group Plc
 Evolutec Group Plc BiotechnologyHealth Technology Evolutec Group Plc is an biopharmaceutical company, which discovers and develops novel biopharmaceuticals for allergic, anti-inflammatory and auto-immune diseases. It was founded in1998 and headquartered in Oxford, United Kingdom. | Corporate Officer/Principal | - |
| Amplion Ltd. | Director/Board Member | - |
Volution Immuno Pharmaceuticals SA
 Volution Immuno Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Part of Akari Therapeutics Plc, Volution Immuno Pharmaceuticals SA is a Swiss company that develops anti-complement and anti-inflammatory molecules to treat orphan conditions in the autoimmune and inflammatory diseases sectors. The private company is based in Geneva, Switzerland. The company was founded by Raymond Prudo-Chlebosz, who has been the CEO since incorporation. Volution Immuno Pharmaceuticals was acquired by Celsus Therapeutics Plc from RPC Pharma Ltd. on September 18, 2015 for $146.72 million. | Chief Tech/Sci/R&D Officer | - |
Formation de Miles Nunn
| University of Oxford | Doctorate Degree |
| University College London | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AKARI THERAPEUTICS, PLC | Health Technology |
| Entreprise privées | 3 |
|---|---|
Evolutec Group Plc
Evolutec Group Plc BiotechnologyHealth Technology Evolutec Group Plc is an biopharmaceutical company, which discovers and develops novel biopharmaceuticals for allergic, anti-inflammatory and auto-immune diseases. It was founded in1998 and headquartered in Oxford, United Kingdom. | Health Technology |
Volution Immuno Pharmaceuticals SA
Volution Immuno Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Part of Akari Therapeutics Plc, Volution Immuno Pharmaceuticals SA is a Swiss company that develops anti-complement and anti-inflammatory molecules to treat orphan conditions in the autoimmune and inflammatory diseases sectors. The private company is based in Geneva, Switzerland. The company was founded by Raymond Prudo-Chlebosz, who has been the CEO since incorporation. Volution Immuno Pharmaceuticals was acquired by Celsus Therapeutics Plc from RPC Pharma Ltd. on September 18, 2015 for $146.72 million. | Health Technology |
| Amplion Ltd. |
